Bioweg will build a 10,000-tonne-per-year bacterial cellulose plant in Elsdorf, North Rhine-Westphalia — the largest facility of its kind in Europe and a direct bet on replacing fossil-derived polymers and intentionally added microplastics in personal care formulations.

The German biotechnology company has allocated roughly 60% of its €35 million in venture capital and European Union funding to the first-of-a-kind site, with construction due to start by the end of 2026 and first commercial volumes targeted for 2028.

What is Bioweg making?

The plant will ferment food and agricultural side streams — primarily molasses from an adjacent sugar complex — into biodegradable bacterial cellulose. In cosmetics, personal care and home care, the resulting ingredients deliver:

• Texture enhancement
• Rheology control
• Suspending properties
• Film-forming
• Sensory modification

The company positions the output as a drop-in replacement for synthetic rheology modifiers and plastic microbeads. Product families already commercialised include MicBeads (micro-powders), RheoWeg (rheology control) and AgriWeg (seed and fertiliser coatings).

Why does the location matter?

Bioweg is building the facility inside one of Germany's largest sugar industrial complexes. Co-locating fermentation feedstock production with the plant cuts logistics emissions, lowers operating costs and locks in raw material supply — a critical consideration for formulators wary of the supply shocks that have repeatedly hit the synthetic polymer market since 2020.

The Quakenbrück demonstration site, which produces around 100 tonnes a year today, is being upgraded to at least 200 tonnes. It will continue supplying commercial batches through 2027 and 2028 and serve as the automation blueprint for Elsdorf.

Who is behind the project?

Bioweg was founded in 2019 by Dr Prateek Mahalwar and Srinivas Karuturi. The company operates a formulation, material science and applications lab on the Monheim campus of Bayer Crop Science.

Dr Prateek Mahalwar, Bioweg co-founder and CEO, said: "Financing a first-of-a-kind plant is the hardest step in industrial biotechnology, and it is the step we are now taking, with the German government and the EU sharing the risk of building."

"Food and agricultural side streams will always be available locally in Europe, and Elsdorf is where we'll turn them into high-performance, biodegradable ingredients at industrial scale," he added.

What does it mean for formulators and buyers?

For procurement teams, the Elsdorf plant changes the supply curve. Today's bacterial cellulose ingredients command premium pricing owing to limited fermentation capacity. A roughly 100-fold scale-up at a single European site — from about 100 tonnes at Quakenbrück to 10,000 tonnes at Elsdorf — should compress unit costs and stabilise lead times for buyers reformulating away from microplastics under EU restrictions.

For compliance, the feedstock matters. Bacterial cellulose produced from European sugar side streams offers a documented bio-based, biodegradable, INCI-compatible input, easing the documentation burden on brand owners facing tightening microplastic rules across the EU and several Asian markets.

For treatment-led brands and indie formulators, the relevant data point will be the first RheoWeg and MicBeads commercial batches from Elsdorf in 2028, alongside published performance benchmarks against incumbent synthetic thickeners and exfoliants.

Mona Neubaur, Minister for Economic Affairs and Climate Action, North Rhine-Westphalia, framed the project as part of regional structural change in the Rheinische Revier: "We are tackling a huge problem at its root: microplastics entering our rivers through every wastewater pipe."

"In the Rheinische Revier, we are demonstrating how bacteria can be turned into genuine alternatives — made in North Rhine-Westphalia for the whole of Europe. This is structural change that pays off: new jobs, new value creation, and less dependence on imports," she said.

The next data point to watch: the Elsdorf groundbreaking before the end of 2026, followed by a 2027 commissioning timeline and the first commercial off-takes in 2028.